PHARMACOLOGY EXAM
SIMULATION TEST (REAL EXAM
FORMAT)|| Questions And Answers
With Rationales/Graded A+/2026
Update/100% Correct /Instant
Download
For: Medical, Nursing, Pharmacy Students
Year: 2026 Update
Total Questions: 80+
Instructions: Choose the best answer. Correct answers are highlighted in bold.
Rationales provided.
SECTION A: GENERAL PHARMACOLOGY (Q1–20)
1. A drug with a high therapeutic index is:
a) More likely to be toxic
b) Safer with a wide margin between effective and toxic doses
c) Safer with a wide margin between effective and toxic doses
d) Less potent
Rationale: High therapeutic index = wide safety margin.
2. Bioavailability refers to:
a) Rate of drug excretion
b) Fraction of unchanged drug reaching systemic circulation
c) Drug binding to plasma proteins
d) Volume of distribution
Rationale: Bioavailability = fraction absorbed unchanged into circulation.
3. First-pass effect primarily involves:
a) Renal excretion
,b) Distribution to fat tissues
c) Hepatic metabolism before reaching systemic circulation
d) Binding to albumin
Rationale: First-pass = metabolism in liver/GI tract before systemic circulation.
4. Which route has the fastest onset?
a) Intravenous
b) Intramuscular
c) Subcutaneous
d) Oral
Rationale: IV → immediate and complete absorption.
5. A drug with a half-life of 4 hours reaches steady state in approximately:
a) 8 hours
b) 12 hours
c) 20 hours
d) 48 hours
Rationale: Steady state ≈ 4–5 half-lives → 4h × 5 = 20h.
6. Competitive antagonist:
a) Binds irreversibly to receptor
b) Overcome by increasing agonist concentration
c) Reduces efficacy without changing potency
d) Activates receptor partially
Rationale: Competitive antagonist reversible; surmountable.
7. Which best describes a Phase I clinical trial?
a) Large-scale efficacy
b) Small group healthy volunteers for safety
c) Post-marketing surveillance
d) Comparative effectiveness
Rationale: Phase I = first-in-human, safety and dosing.
8. Zero-order kinetics means:
a) Constant fraction eliminated per hour
b) Constant amount eliminated per hour
, c) Half-life remains constant
d) Dose-dependent clearance only at low doses
Rationale: Zero-order = constant amount/time (e.g., phenytoin, alcohol).
9. CYP450 enzyme induction leads to:
a) Increased drug half-life
b) Decreased drug plasma concentration
c) Increased toxicity
d) Reduced metabolism
Rationale: Induction → faster metabolism → lower drug levels.
10. A drug with large volume of distribution (Vd) indicates:
a) High plasma protein binding only
b) Extensive tissue distribution
c) Poor absorption
d) Rapid renal excretion
Rationale: Large Vd → drug sequestered in tissues.
11. Pharmacodynamics is:
a) What drug does to the body
b) What body does to the drug
c) Drug absorption
d) Drug excretion
Rationale: Pharmacodynamics = drug effects and mechanism.
12. Which receptor type is linked to G-proteins?
a) Nicotinic ACh receptor
b) Beta-1 adrenergic receptor
c) Insulin receptor
d) Voltage-gated sodium channel
Rationale: Beta-1 is GPCR.
13. A drug with narrow therapeutic window requires:
a) Less frequent dosing
b) Therapeutic drug monitoring
c) Ignoring drug levels
d) IV only
SIMULATION TEST (REAL EXAM
FORMAT)|| Questions And Answers
With Rationales/Graded A+/2026
Update/100% Correct /Instant
Download
For: Medical, Nursing, Pharmacy Students
Year: 2026 Update
Total Questions: 80+
Instructions: Choose the best answer. Correct answers are highlighted in bold.
Rationales provided.
SECTION A: GENERAL PHARMACOLOGY (Q1–20)
1. A drug with a high therapeutic index is:
a) More likely to be toxic
b) Safer with a wide margin between effective and toxic doses
c) Safer with a wide margin between effective and toxic doses
d) Less potent
Rationale: High therapeutic index = wide safety margin.
2. Bioavailability refers to:
a) Rate of drug excretion
b) Fraction of unchanged drug reaching systemic circulation
c) Drug binding to plasma proteins
d) Volume of distribution
Rationale: Bioavailability = fraction absorbed unchanged into circulation.
3. First-pass effect primarily involves:
a) Renal excretion
,b) Distribution to fat tissues
c) Hepatic metabolism before reaching systemic circulation
d) Binding to albumin
Rationale: First-pass = metabolism in liver/GI tract before systemic circulation.
4. Which route has the fastest onset?
a) Intravenous
b) Intramuscular
c) Subcutaneous
d) Oral
Rationale: IV → immediate and complete absorption.
5. A drug with a half-life of 4 hours reaches steady state in approximately:
a) 8 hours
b) 12 hours
c) 20 hours
d) 48 hours
Rationale: Steady state ≈ 4–5 half-lives → 4h × 5 = 20h.
6. Competitive antagonist:
a) Binds irreversibly to receptor
b) Overcome by increasing agonist concentration
c) Reduces efficacy without changing potency
d) Activates receptor partially
Rationale: Competitive antagonist reversible; surmountable.
7. Which best describes a Phase I clinical trial?
a) Large-scale efficacy
b) Small group healthy volunteers for safety
c) Post-marketing surveillance
d) Comparative effectiveness
Rationale: Phase I = first-in-human, safety and dosing.
8. Zero-order kinetics means:
a) Constant fraction eliminated per hour
b) Constant amount eliminated per hour
, c) Half-life remains constant
d) Dose-dependent clearance only at low doses
Rationale: Zero-order = constant amount/time (e.g., phenytoin, alcohol).
9. CYP450 enzyme induction leads to:
a) Increased drug half-life
b) Decreased drug plasma concentration
c) Increased toxicity
d) Reduced metabolism
Rationale: Induction → faster metabolism → lower drug levels.
10. A drug with large volume of distribution (Vd) indicates:
a) High plasma protein binding only
b) Extensive tissue distribution
c) Poor absorption
d) Rapid renal excretion
Rationale: Large Vd → drug sequestered in tissues.
11. Pharmacodynamics is:
a) What drug does to the body
b) What body does to the drug
c) Drug absorption
d) Drug excretion
Rationale: Pharmacodynamics = drug effects and mechanism.
12. Which receptor type is linked to G-proteins?
a) Nicotinic ACh receptor
b) Beta-1 adrenergic receptor
c) Insulin receptor
d) Voltage-gated sodium channel
Rationale: Beta-1 is GPCR.
13. A drug with narrow therapeutic window requires:
a) Less frequent dosing
b) Therapeutic drug monitoring
c) Ignoring drug levels
d) IV only
